<Header>
<FileStats>
    <FileName>20241018_10-Q-A_edgar_data_1847903_0001193125-24-239617.txt</FileName>
    <GrossFileSize>265419</GrossFileSize>
    <NetFileSize>14841</NetFileSize>
    <NonText_DocumentType_Chars>59979</NonText_DocumentType_Chars>
    <HTML_Chars>66604</HTML_Chars>
    <XBRL_Chars>67979</XBRL_Chars>
    <XML_Chars>50295</XML_Chars>
    <N_Exhibits>7</N_Exhibits>
</FileStats>
<SEC-Header>
0001193125-24-239617.hdr.sgml : 20241018
<ACCEPTANCE-DATETIME>20241018160101
ACCESSION NUMBER:		0001193125-24-239617
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20241018
DATE AS OF CHANGE:		20241018

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Centessa Pharmaceuticals plc
		CENTRAL INDEX KEY:			0001847903
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40445
		FILM NUMBER:		241380727

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT
		BUSINESS PHONE:		44 7391 789784

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Centessa Pharmaceuticals Ltd
		DATE OF NAME CHANGE:	20210224

</SEC-Header>
</Header>

 0001193125-24-239617.txt : 20241018

10-Q/A
 1
 d825263d10qa.htm
 10-Q/A

10-Q/A 

UNITED STATES 

 SECURITIES AND EXCHANGE COMMISSION 

 Washington, D.C. 20549 

FORM 

(Amendment No. 1) 

(Mark One) 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 For the quarterly period ended 

 OR 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 For the transition period from to 

 Commission file number 

(Exact name of registrant as specified in its charter) 

(State or other jurisdiction of

 incorporation or organization)

(I.R.S. Employer

 Identification No.)

(Address of principal executive offices and zip code) 

 + 

Registrant s telephone number, including area code 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class

Trading

 Symbol(s)

Name of each exchange

 on which registered

Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market, LLC. 
 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. No 
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). No 
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
 filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2
 of the Exchange Act. 

Large accelerated filer 

Accelerated filer 

Smaller reporting company 

Emerging growth company 
 
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2
 of the Act). Yes No 
 The registrant had outstanding ordinary shares as of August 1, 2024. 

EXPLANATORY NOTE This Amendment No. 1 to the Quarterly Report on Form 10-Q of Centessa Pharmaceuticals plc (the Company for the quarterly period ended June 30, 2024, originally filed with the Securities and Exchange Commission on August 13, 2024 (the Original Filing ), is being filed solely to correct a typographical error contained in Exhibit 31.2 submitted with the Original Filing, and includes the certifications of the Company s principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended. Except as described above, no other changes have been made to the Original Filing, and this Form 10-Q/A does not modify, amend or update in any way any of the financial or other information contained in the Original Filing. This Form 10-Q/A does not reflect events that may have occurred subsequent to the filing date of the Original Filing. 
 2 

Item 6. Exhibits 

Exhibit number 
 
 Description of exhibit 

3.1 
 
 Articles of Association of the registrant, as currently in effect (incorporated by reference to Exhibit 3.1 to the Registrant s Current Report on Form 8-K filed on October 6, 2022 (File No. 001-40445)). 

4.1 
 
 Form of Deposit Agreement (incorporated by reference to Exhibit 4.1 to the Registrant s Registration Statement on Form S-1 (File No. 333-255393)). 

4.2 
 
 Form of American Depositary Receipt (included in Exhibit 4.1) (incorporated by reference to Exhibit 4.2 to the Registrant s Registration Statement on Form S-1 (File No. 333-255393)). 

10.1# 
 
 Employment Agreement, dated June 5, 2024, between the Registrant and John Crowley (incorporated by reference to Exhibit 10.1 to the Registrant s Quarterly Report on Form 10-Q filed on August 13, 2024 (File No. 001-40445)). 

10.2# 
 
 Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement, dated June 5, 2024, between the Registrant and John Crowley (incorporated by reference to Exhibit 10.2 to the Registrant s Quarterly Report on Form 10-Q filed on August 13, 2024 (File No. 001-40445)). 

31.1 
 
 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (1) 

31.2 
 
 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (1) 

32.1 
 
 Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (incorporated by reference to Exhibit 32.1 to the Registrant s Quarterly Report on Form 10-Q filed on August 13, 2024 (File No. 001-40445)). 

32.2 
 
 Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (incorporated by reference to Exhibit 32.2 to the Registrant s Quarterly Report on Form 10-Q filed on August 13, 2024 (File No. 001-40445)). 

101 INS 
 
 XBRL Instance Document 
 3 

101 SCH 
 
 XBRL Taxonomy Extension Schema Document 

101 CAL 
 
 XBRL Taxonomy Extension Calculation Document 

101 DEF 
 
 XBRL Taxonomy Extension Definition Linkbase Document 

101 LAB 
 
 XBRL Taxonomy Extension Labels Linkbase Document 

101 PRE 
 
 XBRL Taxonomy Extension Presentation Link Document 

104 
 
 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibit 101.) 

(1) 
 Filed herewith 

This certification will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing. 

# 
 Indicates a management contract or any compensatory plan, contract or arrangement. 
 4 

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

CENTESSA PHARMACEUTICALS PLC 

Date: October 18, 2024 

By: 
 
 /s/ Saurabh Saha, M.D., Ph.D. 

Name: Saurabh Saha, M.D., Ph.D. 

Title: Chief Executive Officer (Principal Executive Officer) 

Date: October 18, 2024 

By: 
 
 /s/ John Crowley 

Name: John Crowley 

Title: Chief Financial Officer (Principal Financial Officer) 
 
 5 

<EX-31.1>
 2
 d825263dex311.htm
 EX-31.1

EX-31.1 

Exhibit 31.1 
 CERTIFICATION PURSUANT TO 
 RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE
ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 
 I, Saurabh Saha, certify that: 1. I have reviewed this
Quarterly Report on Form 10-Q of Centessa Pharmaceuticals plc; 2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The
registrant s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
 (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 
 (c) Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
 (d) Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the
registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over
financial reporting; and 5. The registrant s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant s auditors and the audit committee of the registrant s board of directors (or persons performing the equivalent functions): 
 (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; and 
 (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s
internal control over financial reporting. 

Date: October 18, 2024 

By: 
 
 /s/ Saurabh Saha 

Saurabh Saha 

Chief Executive Officer 

Principal Executive Officer 

</EX-31.1>

<EX-31.2>
 3
 d825263dex312.htm
 EX-31.2

EX-31.2 

Exhibit 31.2 
 CERTIFICATION PURSUANT TO 
 RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE
ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 
 I, John Crowley, certify that: 1. I have reviewed this
Quarterly Report on Form 10-Q of Centessa Pharmaceuticals plc; 2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The
registrant s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
 (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 
 (c) Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
 (d) Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the
registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over
financial reporting; and 5. The registrant s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant s auditors and the audit committee of the registrant s board of directors (or persons performing the equivalent functions): 
 (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; and 
 (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s
internal control over financial reporting. 

Date: October 18, 2024 

By: 
 
 /s/ John Crowley 

John Crowley 

Chief Financial Officer 

Principal Financial Officer 

</EX-31.2>

<EX-101.SCH>
 4
 cnta-20240630.xsd
 XBRL TAXONOMY EXTENSION SCHEMA

</EX-101.CAL>

<EX-101.DEF>
 6
 cnta-20240630_def.xml
 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

</EX-101.DEF>

<EX-101.LAB>
 7
 cnta-20240630_lab.xml
 XBRL TAXONOMY EXTENSION LABEL LINKBASE

</EX-101.LAB>

<EX-101.PRE>
 8
 cnta-20240630_pre.xml
 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

</EX-101.PRE>

